Supplemental β-carotene, smoking, and urinary F2- isoprostane excretion in patients with prior early stage head and neck cancer

Susan T. Mayne, Mary Walter, Brenda Cartmel, W. Jarrard Goodwin, Jeffrey Blumberg

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Supplemental β-carotene has been shown to increase lung cancer risk in recent chemoprevention trials, especially in current smokers. Several possible mechanisms for this effect have been suggested based upon in vitro and animal studies, but mechanistic data from human studies to explain the excess risk are lacking. β-Carotene has both antioxidant and prooxidant effects in vitro; therefore, we evaluated whether or not high-dose supplemental β-carotene might have prooxidant effects in vivo, especially in current smokers taking high-dose supplemental β-carotene for several years (median 4.0 yr). Urine samples (n = 55 total) were collected from both smokers and nonsmokers participating in a multiyear randomized chemoprevention trial of supplemental β-carotene (50 mg/day) versus placebo. Samples were analyzed by GC/MS for total isoprostanes and for 8-iso-prostaglandin F (8-iso-PGF), stable end products of lipid peroxidation in vivo. Smokers had higher levels of both total isoprostanes and 8-iso-PGF . Smokers and nonsmokers randomized to β-carotene had nonsignificantly lower concentrations of total isoprostanes and of 8-iso-PGF [mean ± SD 8-iso-PGF/ml = 2.00 ± 1.72 (placebo smoker); 1.72 ± 1.66 (β-carotene smoker); 1.22 ± 0.68 (placebo non-smoker); 0.97 ± 0.62 (β-carotene nonsmoker)]. These results indicate that supplemental β-carotene, even when given at high doses for many years, does not have prooxidant effects in either smokers or nonsmokers, as measured by urinary excretion of F2-isoprostanes.

Original languageEnglish
Pages (from-to)1-6
Number of pages6
JournalNutrition and Cancer
Volume49
Issue number1
StatePublished - Oct 11 2004

Fingerprint

F2-Isoprostanes
Carotenoids
carotenes
Head and Neck Neoplasms
8-epi-prostaglandin F2alpha
excretion
Smoking
Dinoprost
prostaglandins
placebos
chemoprevention
Placebos
Chemoprevention
dosage
head and neck neoplasms
Prostaglandins F
lung neoplasms
Lipid Peroxidation
Lung Neoplasms
lipid peroxidation

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Oncology
  • Food Science

Cite this

Supplemental β-carotene, smoking, and urinary F2- isoprostane excretion in patients with prior early stage head and neck cancer. / Mayne, Susan T.; Walter, Mary; Cartmel, Brenda; Goodwin, W. Jarrard; Blumberg, Jeffrey.

In: Nutrition and Cancer, Vol. 49, No. 1, 11.10.2004, p. 1-6.

Research output: Contribution to journalArticle

@article{e87cfe8329e146bb95cd5717a8b8e7d0,
title = "Supplemental β-carotene, smoking, and urinary F2- isoprostane excretion in patients with prior early stage head and neck cancer",
abstract = "Supplemental β-carotene has been shown to increase lung cancer risk in recent chemoprevention trials, especially in current smokers. Several possible mechanisms for this effect have been suggested based upon in vitro and animal studies, but mechanistic data from human studies to explain the excess risk are lacking. β-Carotene has both antioxidant and prooxidant effects in vitro; therefore, we evaluated whether or not high-dose supplemental β-carotene might have prooxidant effects in vivo, especially in current smokers taking high-dose supplemental β-carotene for several years (median 4.0 yr). Urine samples (n = 55 total) were collected from both smokers and nonsmokers participating in a multiyear randomized chemoprevention trial of supplemental β-carotene (50 mg/day) versus placebo. Samples were analyzed by GC/MS for total isoprostanes and for 8-iso-prostaglandin F2α (8-iso-PGF2α), stable end products of lipid peroxidation in vivo. Smokers had higher levels of both total isoprostanes and 8-iso-PGF 2α. Smokers and nonsmokers randomized to β-carotene had nonsignificantly lower concentrations of total isoprostanes and of 8-iso-PGF2α [mean ± SD 8-iso-PGF2α/ml = 2.00 ± 1.72 (placebo smoker); 1.72 ± 1.66 (β-carotene smoker); 1.22 ± 0.68 (placebo non-smoker); 0.97 ± 0.62 (β-carotene nonsmoker)]. These results indicate that supplemental β-carotene, even when given at high doses for many years, does not have prooxidant effects in either smokers or nonsmokers, as measured by urinary excretion of F2-isoprostanes.",
author = "Mayne, {Susan T.} and Mary Walter and Brenda Cartmel and Goodwin, {W. Jarrard} and Jeffrey Blumberg",
year = "2004",
month = "10",
day = "11",
language = "English",
volume = "49",
pages = "1--6",
journal = "Nutrition and Cancer",
issn = "0163-5581",
publisher = "Routledge",
number = "1",

}

TY - JOUR

T1 - Supplemental β-carotene, smoking, and urinary F2- isoprostane excretion in patients with prior early stage head and neck cancer

AU - Mayne, Susan T.

AU - Walter, Mary

AU - Cartmel, Brenda

AU - Goodwin, W. Jarrard

AU - Blumberg, Jeffrey

PY - 2004/10/11

Y1 - 2004/10/11

N2 - Supplemental β-carotene has been shown to increase lung cancer risk in recent chemoprevention trials, especially in current smokers. Several possible mechanisms for this effect have been suggested based upon in vitro and animal studies, but mechanistic data from human studies to explain the excess risk are lacking. β-Carotene has both antioxidant and prooxidant effects in vitro; therefore, we evaluated whether or not high-dose supplemental β-carotene might have prooxidant effects in vivo, especially in current smokers taking high-dose supplemental β-carotene for several years (median 4.0 yr). Urine samples (n = 55 total) were collected from both smokers and nonsmokers participating in a multiyear randomized chemoprevention trial of supplemental β-carotene (50 mg/day) versus placebo. Samples were analyzed by GC/MS for total isoprostanes and for 8-iso-prostaglandin F2α (8-iso-PGF2α), stable end products of lipid peroxidation in vivo. Smokers had higher levels of both total isoprostanes and 8-iso-PGF 2α. Smokers and nonsmokers randomized to β-carotene had nonsignificantly lower concentrations of total isoprostanes and of 8-iso-PGF2α [mean ± SD 8-iso-PGF2α/ml = 2.00 ± 1.72 (placebo smoker); 1.72 ± 1.66 (β-carotene smoker); 1.22 ± 0.68 (placebo non-smoker); 0.97 ± 0.62 (β-carotene nonsmoker)]. These results indicate that supplemental β-carotene, even when given at high doses for many years, does not have prooxidant effects in either smokers or nonsmokers, as measured by urinary excretion of F2-isoprostanes.

AB - Supplemental β-carotene has been shown to increase lung cancer risk in recent chemoprevention trials, especially in current smokers. Several possible mechanisms for this effect have been suggested based upon in vitro and animal studies, but mechanistic data from human studies to explain the excess risk are lacking. β-Carotene has both antioxidant and prooxidant effects in vitro; therefore, we evaluated whether or not high-dose supplemental β-carotene might have prooxidant effects in vivo, especially in current smokers taking high-dose supplemental β-carotene for several years (median 4.0 yr). Urine samples (n = 55 total) were collected from both smokers and nonsmokers participating in a multiyear randomized chemoprevention trial of supplemental β-carotene (50 mg/day) versus placebo. Samples were analyzed by GC/MS for total isoprostanes and for 8-iso-prostaglandin F2α (8-iso-PGF2α), stable end products of lipid peroxidation in vivo. Smokers had higher levels of both total isoprostanes and 8-iso-PGF 2α. Smokers and nonsmokers randomized to β-carotene had nonsignificantly lower concentrations of total isoprostanes and of 8-iso-PGF2α [mean ± SD 8-iso-PGF2α/ml = 2.00 ± 1.72 (placebo smoker); 1.72 ± 1.66 (β-carotene smoker); 1.22 ± 0.68 (placebo non-smoker); 0.97 ± 0.62 (β-carotene nonsmoker)]. These results indicate that supplemental β-carotene, even when given at high doses for many years, does not have prooxidant effects in either smokers or nonsmokers, as measured by urinary excretion of F2-isoprostanes.

UR - http://www.scopus.com/inward/record.url?scp=4644241890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4644241890&partnerID=8YFLogxK

M3 - Article

C2 - 15454352

AN - SCOPUS:4644241890

VL - 49

SP - 1

EP - 6

JO - Nutrition and Cancer

JF - Nutrition and Cancer

SN - 0163-5581

IS - 1

ER -